Financials
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|
TRVN Catalyst Timeline
Dated clinical, regulatory and corporate events for Trevena, Inc.
Past FDA Catalysts and PDUFA Decisions
How TRVN actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2024-12-31 | TRV045 Optimized | Phase 1 data readout | Phase 1 |
Drug Pipeline Intelligence
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| TRV130 Small MoleculesMarketedNCT02083315 | Acute Pain | Approved | COMPLETED | 1,131 | Aug 1, 2013 | ||||||
| Oliceridine Small MoleculesMarketedNCT02820324 | Acute Pain | Approved | COMPLETED | 825 | Jan 1, 2017 | ||||||
| TRV130 Small MoleculesMarketedNCT02335294 | Pain | Approved | COMPLETED | 200 | Aug 1, 2015 |
Clinical Trial Results
Readouts, endpoints and source filings for every TRVN program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| TRV045 | CNS disorders | 2023-11-14 | no drug-related adverse events, no serious adverse events and no study drug-related discontinuations reportedRead More | Trevena Reports Third Quarter 2023 Results and Provides Business Update Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action andRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Shin BarryOfficer (SVP, CFO) | Sell | -31,785 873,056 held | $0.41 | 06/28/2022 |
Hedge Fund 13F Activity
Hedge Funds invested in TRVN
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| NEA Management Company, LLC | 0.1 % | 4.69 M | 3.81 M |
Ownership Trends
TRVN Short Interest
Shares sold short, counted twice a month.
Options Data
Option Volume
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
Competitive positioning
How TRVN ranks across every disease it competes in
TRVN News
Trevena Reports Third Quarter 2024 Results and Provides Business Update CHESTERBROOK, Pa.
Trevena Reports Third Quarter 2024 Results and Provides Business Update CHESTERBROOK, Pa., November 7, 2024 (GLOBE NEWSWIRE) -Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with centra
Read more →Trevena Announces Receipt of Nasdaq Delisting Notification -- CHESTERBROOK, Pa.
Receipt of Nasdaq Delisting Notification CHESTERBROOK, Pa., October 4, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq:TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders
Read more →Trevena Reports Second Quarter 2024 Results and Provides Business Update TRV045, novel S1P receptor modulator in development for the treatment of acute and chronic neuropathic pain and epilepsy, demonstrated sustained lo
Trevena Reports Second Quarter 2024 Results and Provides Business Update TRV045, novel S1P receptor modulator in development for the treatment of acute and chronic neuropathic pain and epilepsy, demonstrated sustained long-term analgesic effect and differentiated mechanism of
Read more →Trevena Announces Reverse Stock Split -- CHESTERBROOK, Pa.
Trevena Announces Reverse Stock Split Pa., August 8, 2024 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced
Read more →Trevena Announces $2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing Trevena expects to receive a non-dilutive $2 million tranche and may be el
$2M Non-Dilutive Financing Tranche and Reduction in Outstanding Liabilities in Connection with Existing ex-US Royalty Financing to receive a non-dilutive $2 million tranche and may be eligible for up to an additional $8 million based on OLINYVK US partnering and commercializat
Read more →Trevena Reports First Quarter 2024 Results and Provides Business Update TRV045, novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile Ongoing clinical PK st
Reports First Quarter 2024 Results and Provides Business Update novel S1P receptor modulator for chronic pain and epilepsy, continues to demonstrate a favorable tolerability profile clinical PK study with optimized formulation of TRV045 advances, with data expected 2H 2024 Pa.
Read more →Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies
Fourth Quarter 2023 Results and Provides Corporate Update TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies announces reduction of OLINVYK commercial support and review of alternat
Read more →INNOVATING FOR PATIENTS Nasdaq: TRVN I January 2024 Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Trevena, Inc. (the “Co
Health care providers and family members monitoring patients receiving PCA analgesia should be instructed in the need for appropriate monitoring for excessive sedation, respiratory depression, or other adverse effects of opioid medications. ADVERSE REACTIONS Adverse reactions are
Read more →Trevena Inc. Announces $4 Million Concurrent Private Placement and Warrant Exercise CHESTERBROOK, Pa.
Trevena Inc. Announces $4 Million Concurrent Private Placement and CHESTERBROOK, Pa., Dec. 27, 2023 -- Trevena Inc. ("Trevena" or the "Company") (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with ce
Read more →Trevena Reports Third Quarter 2023 Results and Provides Business Update Company previously announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and
Third Quarter 2023 Results and Provides Business Update announced statistically significant topline TRV045 data from two proof-of-concept studies evaluating S1PR mechanism of action and CNS favorable safety and tolerability data from TRV045 POC studies for OLINVYK presented at
Read more →INNOVATING FOR PATIENTS Nasdaq: TRVN I October 2023 Forward-Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Trevena, Inc. (the “Co
Health care providers and family members monitoring patients receiving PCA analgesia should be instructed in the need for appropriate monitoring for excessive sedation, respiratory depression, or other adverse effects of opioid medications. ADVERSE REACTIONS Adverse reactions are
Read more →INNOVATING FOR PATIENTS Nasdaq: TRVN I September 2023 Forward - Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Trevena, Inc. (t he "Comp
INNOVATING FOR PATIENTS Nasdaq: TRVN I September 2023 Forward - Looking Statements To the extent that statements contained in this presentation are not descriptions of historical facts regarding Trevena, Inc. (t he "Company" or "we"), they are forward - looking statements reflec
Read more →Trevena Reports Second Quarter 2023 Results and Provides Business Update Company announces database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy; topline data expected 3Q 2023 TRV04
Second Quarter 2023 Results and Provides Business Update database lock for TRV045 proof-of-concept TMS study evaluating potential for use in epilepsy; topline data expected 3Q 2023 TRV045 proof-of-concept study evaluating potential for use in acute and chronic pain advancing w
Read more →Trevena, Inc. Appoints Mark Corrigan, M.D. to Board of Directors CHESTERBROOK, Pa.
Appoints Mark Corrigan, M.D. to Board of Directors CHESTERBROOK, Pa., July 20, 2023, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system
Read more →Trevena Announces New Topline OLINVYK Data Highlighting Reduced Cost per Admission from ARTEMIS Real-World Outcomes Study OLINVYK-treated patients (n=201) had a statistically significant ~$8,750 (19%) lower cost per admi
New Topline OLINVYK Data Highlighting per Admission from ARTEMIS Real-World Outcomes Study patients (n=201) had a statistically significant ~$8,750 (19%) lower cost per admission and ~1.4 day (20%) reduced average length of hospital stay, compared to matched patients treated w
Read more →Trevena Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term Milestones CHESTERBROOK, Pa.
Regains Compliance with Nasdaq Listing and Reaffirms Expected Near-Term Milestones Pa., May 30, 2023 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nerv
Read more →Trevena Reports First Quarter 2023 Results and Provides Business Update OLINVYK receives regulatory approval in China, triggering $3 million milestone payment from Company's China partner Jiangsu Nhwa Pharmaceutical Comp
Trevena Reports First Quarter 2023 Results and Provides Business Update OLINVYK receives regulatory approval in China, triggering $3 million milestone payment from Company's China partner Jiangsu Nhwa Pharmaceutical Company expects to receive additional $15 million non-dilut
Read more →Trevena to Release First Quarter 2023 Financial Results on
Trevena to Release First Quarter 2023 Financial Results on May 15, 2023 Company to host a Conference Call & Webcast at 8:00 a.m. ET CHESTERBROOK, Pa., May 9, 2023 -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of
Read more →Trevena Announces Approval of OLINVYK in China Trevena's partner, Jiangsu Nhwa, receives approval from Chinese National Medical Products Administration (NMPA) Approval achieves $3 million milestone to Trevena from Jiangs
Approval of OLINVYK in China partner, Jiangsu Nhwa, receives approval from Chinese National Medical Products Administration (NMPA) $3 million milestone to Trevena from Jiangsu Nhwa million to Trevena expected on first commercial sale in China, based on ex-US Royalty-Based Fina
Read more →Trevena Announces Initial Topline OLINVYK Data from ~200 Patient Real-World Clinical Outcomes Study OLINVYK-treated patients had a statistically significant 1.6 day (~27%) reduction in average overall hospital length of
Initial Topline OLINVYK Data from Real-World Clinical Outcomes Study patients had a statistically significant 1.6 day (~27%) reduction in average overall hospital length of stay compared to matched patients treated with other IV opioids, based on initial EMR analysis of ARTEMI
Read more →